SEC Form 4 · accession 0001104659-26-108326
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip P. Chan
Officer — Chief Executive Officer · Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 16, 2026 · 5:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Sep 15, 2026 | P | 3,774 | $6.00 | A | 100,996 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
- F2Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015;
- F3(continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person.
- F4Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.